Presentation:  Emerging Treatment Landscape: Impact of Paradigm Shifts on Therapeutic Selection
> Pretest

1. Which of the following MS DMTs has been removed from the market?

a. Ibudilast

b. Cladribine

c. Daclizumab

d. Mitoxantrone

e. Ofatumumab

2. Which of the following statements about the phase III ORATORIO ocrelizumab PPMS trial is true?

a. It entered PPMS up to age 65

b. There was no progression effect in women

c. It entered some nonambulatory PPMS

d. You could have PPMS up to 20 years

e. It required spinal cord MRI lesions